Agilent Technologies, Inc. (Santa Clara, California)’ Next-Generation-Sequencing Human Exome Target Enrichment Portfolio Now Available for SOLiD(TM)

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that its SureSelect Human All Exon Kit is now available for the Applied Biosystems SOLiD System. Applied Biosystems is part of Life Technologies Corp. The kit enables target enrichment prior to next-generation DNA sequencing.